Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
GRA Ex-25
Cat. No.:
OB0225LY-0271
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
GRA Ex-25 is a glucagon receptor inhibitor.
Synonym:
307983-31-9; 3-[[4-[[(4-tert-Butylcyclohexyl)-[[4-(trifluoromethoxy)phenyl]carbamoyl]amino]methyl]benzoyl]amino]propanoic acid; 3-(4-((1-(trans-4-(tert-Butyl)cyclohexyl)-3-(4-(trifluoromethoxy)phenyl)ureido)methyl)benzamido)propanoic acid; 3-{4-[1-(4-tert-Butyl-cyclohexyl)-3-(4-trifluoromethoxy-phenyl)-ureidomethyl]-benzoylamino}-propionic acid
CAS No.:
307983-31-9
Compound CID:
16100296
Formula:
C29H36F3N3O5
Formula Weight:
563.61
Specification
Relative Density:
1.28 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
GRA Ex-25 can be used in biomedical research, as a tool for biomarker selection, or play an important role in drug screening.
Library Information
Targets:
Glucagon receptor
Pathways:
GPCR/G protein
Plate Number:
AOCL-4
Plate Location:
d10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 88.71 mM
